Uncategorized
SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, Inc. announced positive top-line results of a Phase 1/2 study of SF0166 for the topical treatment of patients with DME.